Home
Science
Therapeutic Strategy
Team
News
Contact

Contact

Recent Posts

Visgenx Announces Presentation of Data Supporting Potential of its Synthetic AAV DNA Platform for Gene Editing at ASGCT
ASGCT 2024 Poster Abstract
ELOVL2 Enzyme Product Improves Retinal Function and Rejuvenates Retina Architecture in an Aged Mouse Model of AMD
Visgenx to Present at the Second Annual 2024 Cell & Gene Therapy Summit
Visgenx selected as a ‘2024 Cool Company’

Archives

May 2024
April 2024
December 2023
November 2023
October 2023
September 2023
June 2023
May 2023

Categories

Uncategorized

Archives

May 2024
April 2024
December 2023
November 2023
October 2023
September 2023
June 2023
May 2023

Month: October 2023

25.10.2023

Visgenx Announces Issuance of a U.S. Patent Claiming Compositions of Candidate ELOVL2...

»

Visgenx, Inc. © 2024. All Rights Reserved.

Privacy Policy Terms of Use

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.AcceptPrivacy Policy